FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021911387> ?p ?o ?g. }

• W2021911387 endingPage "974" @default.
• W2021911387 startingPage "961" @default.
• W2021911387 abstract "We conducted a trial to compare treatment with zidovudine or didanosine in patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who had received little or no previous therapy with zidovudine.Six hundred seventeen patients with acquired immunodeficiency syndrome (AIDS), advanced AIDS-related complex (CD4 cell count, < or = 0.30 x 10(9)/L [300/microL]), or asymptomatic HIV (CD4 cell count, < or = 0.20 x 10(9)/L) received zidovudine, 500 mg/d of didanosine, or 750 mg/d of didanosine in a randomized, double-blind allocation, with cross-over to alternative medication after development of an end point or serious toxic effect. To be eligible, patients must have received either no or up to 16 weeks of zidovudine therapy before entry into the study. Primary end points were development of a new AIDS-defining event or death. Secondary clinical end points were new or recurrent AIDS-defining events, or death, and survival.In the study as a whole, there were no differences in the relative risks (RRs) of the development of end points between treatment groups. However, there was a strong interaction between the relative efficacies of zidovudine and didanosine and previous experience with zidovudine. Among 380 patients with no previous zidovudine therapy, zidovudine was more effective than 750 mg/d of didanosine (RR, 1.43; 90% confidence interval [CI], 1.02 to 2.00), with a similar trend for zidovudine compared with 500 mg/d of didanosine (RR, 1.21; 90% CI, 0.86 to 1.71). However, among 118 patients with more than 8 weeks but no more than 16 weeks of previous zidovudine therapy, 500 mg/d of didanosine was more effective than zidovudine (RR, 0.48; 90% CI, 0.27 to 0.86); there was a similar trend for increased effectiveness of 750 mg/d of didanosine compared with zidovudine (RR, 0.61; 90% CI, 0.36 to 1.03). Among 119 patients who had some but no more than 8 weeks of previous zidovudine therapy, there were no significant differences among the treatment arms. Similar findings were noted in the analysis of the two secondary clinical end points. No significant differences were found in efficacy between the groups receiving 500 and 750 mg/d of didanosine. The major toxic effect associated with zidovudine was hematopoietic (granulocytopenia) and that associated with didanosine was pancreatitis (dosage, 750 mg/d).In patients with advanced HIV disease, zidovudine appears to be more effective than didanosine as initial therapy; however, some patients with advanced HIV disease may benefit from a change to didanosine therapy after as little as 8 to 16 weeks of therapy with zidovudine." @default.
• W2021911387 created "2016-06-24" @default.
• W2021911387 creator A5002019456 @default.
• W2021911387 creator A5012623658 @default.
• W2021911387 creator A5015287602 @default.
• W2021911387 creator A5030636201 @default.
• W2021911387 creator A5031229975 @default.
• W2021911387 creator A5037748434 @default.
• W2021911387 creator A5040147911 @default.
• W2021911387 creator A5073703562 @default.
• W2021911387 creator A5083165826 @default.
• W2021911387 creator A5084232309 @default.
• W2021911387 date "1995-05-08" @default.
• W2021911387 modified "2023-10-11" @default.
• W2021911387 title "Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group" @default.
• W2021911387 doi "https://doi.org/10.1001/archinte.155.9.961" @default.
• W2021911387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7726705" @default.
• W2021911387 hasPublicationYear "1995" @default.
• W2021911387 type Work @default.
• W2021911387 sameAs 2021911387 @default.
• W2021911387 citedByCount "31" @default.
• W2021911387 crossrefType "journal-article" @default.
• W2021911387 hasAuthorship W2021911387A5002019456 @default.
• W2021911387 hasAuthorship W2021911387A5012623658 @default.
• W2021911387 hasAuthorship W2021911387A5015287602 @default.
• W2021911387 hasAuthorship W2021911387A5030636201 @default.
• W2021911387 hasAuthorship W2021911387A5031229975 @default.
• W2021911387 hasAuthorship W2021911387A5037748434 @default.
• W2021911387 hasAuthorship W2021911387A5040147911 @default.
• W2021911387 hasAuthorship W2021911387A5073703562 @default.
• W2021911387 hasAuthorship W2021911387A5083165826 @default.
• W2021911387 hasAuthorship W2021911387A5084232309 @default.
• W2021911387 hasConcept C126322002 @default.
• W2021911387 hasConcept C203014093 @default.
• W2021911387 hasConcept C2777447569 @default.
• W2021911387 hasConcept C2780216070 @default.
• W2021911387 hasConcept C2780727368 @default.
• W2021911387 hasConcept C3013748606 @default.
• W2021911387 hasConcept C535046627 @default.
• W2021911387 hasConcept C71924100 @default.
• W2021911387 hasConceptScore W2021911387C126322002 @default.
• W2021911387 hasConceptScore W2021911387C203014093 @default.
• W2021911387 hasConceptScore W2021911387C2777447569 @default.
• W2021911387 hasConceptScore W2021911387C2780216070 @default.
• W2021911387 hasConceptScore W2021911387C2780727368 @default.
• W2021911387 hasConceptScore W2021911387C3013748606 @default.
• W2021911387 hasConceptScore W2021911387C535046627 @default.
• W2021911387 hasConceptScore W2021911387C71924100 @default.
• W2021911387 hasIssue "9" @default.
• W2021911387 hasLocation W20219113871 @default.
• W2021911387 hasLocation W20219113872 @default.
• W2021911387 hasOpenAccess W2021911387 @default.
• W2021911387 hasPrimaryLocation W20219113871 @default.
• W2021911387 hasRelatedWork W2021911387 @default.
• W2021911387 hasRelatedWork W204038522 @default.
• W2021911387 hasRelatedWork W2075050095 @default.
• W2021911387 hasRelatedWork W2115053576 @default.
• W2021911387 hasRelatedWork W2121680315 @default.
• W2021911387 hasRelatedWork W2155455149 @default.
• W2021911387 hasRelatedWork W2322276116 @default.
• W2021911387 hasRelatedWork W2334005831 @default.
• W2021911387 hasRelatedWork W2339921515 @default.
• W2021911387 hasRelatedWork W2019452982 @default.
• W2021911387 hasVolume "155" @default.
• W2021911387 isParatext "false" @default.
• W2021911387 isRetracted "false" @default.
• W2021911387 magId "2021911387" @default.
• W2021911387 workType "article" @default.